NCT04950751View on ClinicalTrials.gov

Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

candidate vaccine, SCB-2020S

a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY